News

Pediatric patients with moderate to severe eczema demonstrated an increased risk of experiencing the food allergy.

As we have surpassed the halfway mark of 2023, Dermatology Times is spotlighting vitiligo coverage and news from the first half of year.

The American Acne and Rosacea Society brings attention to the negative emotional effects of acne.

New pharmacokinetic phase 3 data will be presented at the 2023 Society for Pediatric Dermatology meeting next week.

The authorization comes just over 2 months after the drug’s approval in the European Union.

Investigators reported that deucravacitnib improved quality of life and clinical outcomes scores in those with moderate to severe psoriasis.

Trained immunity may act as an enhancer and continuous trigger in the disease’s pathogenesis.

In this week’s Pointers With Portela, the 208SkinDoc interviews Ron Robinson, a well-known cosmetic chemist in the skin care industry.

Studies found that skin treated with vitamin C was smoother and less wrinkled than skin treated with a placebo.

Cookouts and fireworks on the 4th of July bring the risk of burns, sometimes severe. Long days at the pool, lake, and beach also increase the risk of sunburn. Here you can check out some past articles that highlight innovations in the treatment of burns and what to look for in sun protection.

It was found that cancer treatment, pediatric population, and coverage restriction of reference products were revealed as some of the strongest factors associated with biosimilar coverage decisions by US commercial health plans relative to reference products.

The recent formulation of benzoyl peroxide in a microencapsulated form improves tolerability while reducing lesions in individuals with rosacea.

Click here to answer this week's poll.

Safety data is promising, but clinicians are encouraged to utilize proper skin cooling mechanisms.

Boehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.

ICYMI, this week we had stories about ritlecitinib approved for adolescents with severe alopecia areata, harmful social media skin care trends, artificial intelligence in dermatology, and more.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of June.

Learn more about the in-depth topics covered in the June 2023 Frontline Forum acne supplement of Dermatology Times®.

Any analysis of physician negligence must first begin with a legal description of the elements of negligence.

In the final part of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

The ongoing Canadian wildfires are causing poor air quality in the US, which will likely result in more patients seeking help for skin conditions.

Learn more about the in-depth topics covered in the June 2023 issue of Dermatology Times®.

The combination of therapies achieved significant efficacy, with researchers noting a higher cure rate than is evident in other therapies for the condition.

Sanofi’s investigational anti-OX40-ligand monoclonal antibody showed statistically significant improvement in signs and symptoms of AD in adults.

The National Rosacea Society has launched a program to identify skin care and cosmetic products that will not irritate sensitive skin.

Findings from several large studies quantify the value that professional advisers bring to dermatology practices. Learn when to hone in on their expertise and when to take matters into your own hands.

The OSIRIS open-label study resulted in a reduction of pain and improvement in quality of life for participants.

Renata Block, PA-C; Raj Chovatiya, MD, PhD; and Zoe Diana Draelos, MD, discuss their optimism and concerns surrounding the increased use of artificial intelligence in dermatology.

The device is now the first of its kind to become available to pediatric patients.